WebMD CEO out after a year

Share this article:
WebMD CEO out after a year
WebMD CEO out after a year

WebMD's Tuesday earnings call included a lot of unanswered questions, such as why Cavan Redmond, who started as CEO on May 31, 2012, is no longer with the company. Execs were unwilling to provide what chairman Martin Wygod called "more color" about the departure. SVP strategic and corporate development David Schlanger will step in as interim CEO until they find someone else to fill the spot on a permanent basis.

Redmond, who joined the company from Pfizer, stepped into a vacancy left by longtime CEO Wayne Gattinella, who resigned in February, 2012 amid declining pharma revenues and an aborted scheme to sell the company. Redmond weathered several tough quarters, culminating in a December announcement that the company would cut 14% of its staff positions, while working to build out WebMD's mobile offering.

Tuesday's call contained suggestions that the company was on the hunt for partnerships and even acquisitions moving forward, despite a quiet two or three years on the M&A front. Wygod kept it vague regarding timing and opportunity.

First quarter revenue was $112.8 million for the quarter, up from $106.9 million for the same period last year. Contributing to this jump was a leap in public portal advertising to $93.4 million, compared to $87.8 million for the same period last year.

Execs said a tweak to the Google algorithm helped goose visits to the WebMD site, which was counterbalanced by fewer visits to its other properties, with 34% of traffic coming from US mobile devices, and 20% of that traffic from tablets.

Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...

Sanofi expands Gaucher disease portfolio

Sanofi expands Gaucher disease portfolio

The oral medication Cerdelga joins Cerezyme in its Gaucher disease arsenal. Sanofi expects the drug will be priced "on par" with Cerezyme, which goes for around $300,000 a year in ...

Amicus seeks to upset Fabry market

Amicus seeks to upset Fabry market

Phase-III tests indicate patients may be able to switch from injectable enzyme-replacement therapies, like Fabrazyme, to the firm's oral drug.